Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JSP191
Briquilimab · 1 trial · 1 indication
Incidence and severity of treatment emergent AEs/SAEs
| Arm | Type | Description |
|---|---|---|
| Briquilimab | EXPERIMENTAL | This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. |
| Placebo | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| Briquilimab | DRUG | Subcutaneous Administration |
| Placebo | OTHER | Placebo Comparator |
Inclusion Criteria: 1. Written informed consent after the nature of the trial has been fully explained and before performing any trial related assessments 2. Males and females, ≥18 years old 3. i. For Cohorts 1, 2, 3, 4a, 4b, 5, 5b, 6 and 7: Diagnosis of symptomatic CSU despite treatment as defined...
Briquilimab is an investigational monoclonal antibody being developed by Jasper Therapeutics, Inc. for the treatment of chronic spontaneous urticaria, a dermatologic condition marked by recurring hives without an identifiable external trigger. It is a Phase 1 clinical-stage candidate and has not been approved by the FDA.
Briquilimab targets KIT, a receptor that plays a central role in the survival and activation of mast cells. As a KIT inhibitor, briquilimab is designed to interfere with KIT signaling, which is the mechanism under investigation for reducing mast cell driven inflammation in chronic spontaneous urticaria.
Briquilimab is being developed by Jasper Therapeutics, Inc., which trades on the Nasdaq under the ticker JSPR. The company is the sponsor of the clinical program evaluating the monoclonal antibody in chronic spontaneous urticaria.
Briquilimab is in Phase 1 clinical development. It is an investigational agent and is not FDA approved. The completed Phase 1 trial evaluated dose escalation, safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in adults with chronic spontaneous urticaria.
Briquilimab has been studied in the Phase 1 trial NCT06162728, titled a dose escalation trial of safety, pharmacokinetic/pharmacodynamic and preliminary clinical activity of briquilimab in adult patients with chronic spontaneous urticaria. The trial enrolled 87 participants across the United States and Germany and is completed.
Briquilimab is being evaluated as a treatment for chronic spontaneous urticaria, a skin condition involving persistent hives. The Phase 1 trial NCT06162728 studied adults 18 years and older of all sexes, was randomized, double blind, and placebo controlled, and enrolled 87 participants.